To The Moon

Tesla's U.S. sales hit nearly 3-year low in NovemberStandard variants cannibalize Premium sales, says Cox's StreatyTesla's market share rises while EV sales slump(Reuters) - Tesla's U.S. sales...

UPDATE 3-Broadcom forecasts upbeat quarterly revenue on AI chip demandAdds analyst comment in paragraph 5By Juby BabuDec 11 (Reuters) - Broadcom AVGO.O on Thursday projected first-quarter revenue abov

US Weekly Initial Jobless Claims 236K (Est. 220K, Prior 192K Revised from 191K)

Eli Lilly and Company announced positive topline results from the Phase 3 TRIUMPH-4 clinical trial evaluating retatrutide, a first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist, in adults with obesity or overweight and knee osteoarthritis. In the trial, participants taking retatrutide 12 mg achieved an average weight loss of 28.7% from baseline at 68 weeks, and experienced a reduction in osteoarthritis pain by up to 4.5 points on the WOMAC pain score. Improvements in physical function were also observed, with more than one in eight patients becoming free from knee pain by the end of the trial. Discontinuation rates due to adverse events were higher in the retatrutide groups compared to placebo. Detailed results from TRIUMPH-4 will be presented at a future medical meeting and published in a peer-reviewed journal. Additional Phase 3 trials in the TRIUMPH program are ongoing, with results expected in 2026.

$Gemini Space Station Inc(GEMI)$, the crypto platform founded by billionaire twins Tyler and Cameron Winklevoss, said on Wednesday it had received a license from the Commodity Futures Trading...

Big tech stocks fell on Thursday as Oracle's results reignited fears about high-flying tech stocks even after the Federal Reserve's latest interest rate cut gave a boost to U.S. equity markets in the...

UPDATE 1-Musk hints at possible SpaceX IPO in X post after media reportsAdds more background from paragraph 5. Dec 10 - Billionaire Elon Musk on Wednesday hinted at a possible SpaceX initial public offering in a social media exchange with Ars Technica space journalist Eric Berger, following reports of a possible listing of the rocket maker in 2026."As usual, Eric is accurate," Musk said, in reply to Berger's post saying "Here's why I think SpaceX is going public soon," that linked his Ars Technica article on SpaceX's plans to go public.Reuters and others reported on Tuesday that SpaceX was looking to raise more than $25 billion through an IPO in 2026, a move that could boost the rocket-maker's valuation to more than $1 trillion.SpaceX did not immediately respond to a request for comment. The California-based company ranks as the world's second most-valuable private startup after ChatGPT maker OpenAI, according to data from Crunchbase. SpaceX going public at the reported valuation wou

$NIO Inc.(NIO)$ It's impossible for Nio to hit $10 this month. Nio may not even rise above $10 in the first half of next year. Too diluted. Short term outlook seems profitable. Long term is very uncertain. Trade carefully. 🍌 🍌 🍌